{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:19:53Z","timestamp":1791685193234,"version":"4.3.4"},"reference-count":24,"publisher":"Japan Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1507\/endocrj.ej17-0276","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T22:17:06Z","timestamp":1516400226000},"page":"359-371","source":"Crossref","is-referenced-by-count":38,"title":["Efficacy and safety of metyrosine in pheochromocytoma\/paraganglioma: a multi-center trial in Japan"],"prefix":"10.1507","volume":"65","author":[{"given":"Mitsuhide","family":"Naruse","sequence":"first","affiliation":[{"name":"Clinical Research Institute for Endocrinology and Metabolic Diseases, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitoshi","family":"Satoh","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University Hospital, Sendai 980-8574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyo","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Tokyo 162-8655, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Surgery II, Tokyo Women\u2019s Medical University, Tokyo 162-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiro","family":"Ichihara","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Hypertension, Tokyo Women\u2019s Medical University, Tokyo 162-8666, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Tsuiki","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuyuki","family":"Katabami","sequence":"additional","affiliation":[{"name":"Department of Metabolism and Endocrinology, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, Yokohama 241-0811, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Kyushu University Hospital, Fukuoka 812-8582, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Molecular Diagnosis, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Urology and Andrology, Kansai Medical University Hospital, Hirakata 573-1191, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneo","family":"Imai","sequence":"additional","affiliation":[{"name":"National Hospital Organization, Higashinagoya National Hospital, Nagoya 465-8620, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Harada","sequence":"additional","affiliation":[{"name":"Ono Pharmaceutical Co., Ltd., Osaka 541-8564, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Kawata","sequence":"additional","affiliation":[{"name":"Ono Pharmaceutical Co., Ltd., Osaka 541-8564, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Takekoshi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Tsukuba, Tsukuba 305-8577, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","volume":"366","author":"JW Lenders","year":"2005","unstructured":"1 Lenders JW, Eisenhofer G, Mannelli M, Pacak K (2005) Phaeochromocytoma. Lancet 366: 665\u2013675.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/MPA.0b013e3181ebb4f0","volume":"39","author":"H Chen","year":"2010","unstructured":"2 Chen H, Sippel RS, O\u2019Dorisio MS, Vinik AI, Lloyd RV, et al. (2010) The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39: 775\u2013783.","journal-title":"Pancreas","ISSN":"https:\/\/id.crossref.org\/issn\/0885-3177","issn-type":"print"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, et al. (2014) Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 21: 405\u2013414.","DOI":"10.1530\/ERC-13-0494"},{"key":"4","unstructured":"4 NCCN clinical practice guidelines in oncology. Neuroendocrine tumors. Version 2.2016. https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed June 15 2017."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, et al. (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99: 1915\u20131942.","DOI":"10.1210\/jc.2014-1498"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, et al. (1988) Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109: 267\u2013273.","DOI":"10.7326\/0003-4819-109-4-267"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Shapiro B, Gross MD, Shulkin B (2001) Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 12: 469\u2013475.","DOI":"10.1016\/S1043-2760(01)00492-1"},{"key":"8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cncr.11518","volume":"98","author":"B Rose","year":"2003","unstructured":"9 Rose B, Matthay KK, Price D, Huberty J, Klencke B, et al. (2003) High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 98: 239\u2013248.","journal-title":"Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/0008-543X","issn-type":"print"},{"key":"9","doi-asserted-by":"crossref","unstructured":"10 Mullen JP, Cartwright RC, Tisherman SE, Misage JR, Shapiro AP (1985) Pathogenesis and pharmacologic management of pseudo-obstruction of the bowel in pheochromocytoma. Am J Med Sci 290: 155\u2013158.","DOI":"10.1097\/00000441-198510000-00004"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11 Robinson RG, DeQuattro V, Grushkin CM, Lieberman E (1977) Childhood pheochromocytoma: treatment with alpha methyl tyrosine for resistant hypertension. J Pediatr 91: 143\u2013147.","DOI":"10.1016\/S0022-3476(77)80467-8"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12 Amery A, Moerman EJ, Bossaert H, de Schaepdryver AF (1969) \u03b1-methyl-p-tyrosine in malignant pheochromocytoma. Pharmacologia Clinica 1: 174\u2013176.","DOI":"10.1007\/BF00456942"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13 Engelman K, Horwitz D, J\u00e9quier E, Sjoerdsma A (1968) Biochemical and pharmacologic effects of alpha-methyltyrosine in man. J Clin Invest 47: 577\u2013594.","DOI":"10.1172\/JCI105754"},{"key":"13","unstructured":"14 Py\u00f6r\u00e4l\u00e4 K, Pitk\u00e4nen E, Toivonen S (1968) Alpha-methyl-p-tyrosine in the symptomatic treatment of patients with malignant phaeochromocytoma. Ann Med Intern Fenn 57: 65\u201373."},{"key":"14","doi-asserted-by":"crossref","unstructured":"15 Jones NF, Walker G, Ruthven CR, Sandler M (1968) Alpha-methyl-p-tyrosine in the management of phaeochromocytoma. Lancet 2: 1105\u20131109.","DOI":"10.1016\/S0140-6736(68)91579-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"16 Bagnall WE, Salway JG, Jackson EW (1976) Phaeochromocytoma with myocarditis managed with alpha-methyl-p-tyrosine. Postgrad Med J 52: 653\u2013656.","DOI":"10.1136\/pgmj.52.612.653"},{"key":"16","unstructured":"17 DEMSER (metyrosine) capsule. FDA prescribing information. https:\/\/www.drugs.com\/pro\/demser.html. Accessed October 31 2016."},{"key":"17","unstructured":"18 ICH harmonized tripartite guideline: guideline for good clinical practice E6 (R1). Current step 4 version 1996. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf. Accessed June 15 2017."},{"key":"18","unstructured":"19 Busner J, Targum SD (2007) The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont) 4: 28\u201337."},{"key":"19","doi-asserted-by":"crossref","unstructured":"20 Steinsapir J, Carr AA, Prisant LM, Bransome ED Jr (1997) Metyrosine and pheochromocytoma. Arch Intern Med 157: 901\u2013906.","DOI":"10.1001\/archinte.1997.00440290087009"},{"key":"20","doi-asserted-by":"crossref","unstructured":"21 Perry RR, Keiser HR, Norton JA, Wall RT, Robertson CN, et al. (1990) Surgical management of pheochromocytoma with the use of metyrosine. Ann Surg 212: 621\u2013628.","DOI":"10.1097\/00000658-199011000-00010"},{"key":"21","unstructured":"22 Kuchel O, Buu NT, Edwards DJ (1990) Alternative catecholamine pathways after tyrosine hydroxylase inhibition in malignant pheochromocytoma. J Lab Clin Med 115: 449\u2013453."},{"key":"22","doi-asserted-by":"crossref","unstructured":"23 Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78: 189\u2013225.","DOI":"10.1152\/physrev.1998.78.1.189"},{"key":"23","unstructured":"24 Brunton LL, Chabner BA, Knollman BC (2011) Goodman & Gilman\u2019s: the pharmacological basis of therapeutics (12th). McGraw-Hill Medical, 288\u2013289."},{"key":"24","doi-asserted-by":"crossref","unstructured":"25 Wachtel H, Kennedy EH, Zaheer S, Bartlett EK, Fishbein L, et al. (2015) Preoperative metyrosine improves cardiovascular outcomes for patients undergoing surgery for pheochromocytoma and paraganglioma. Ann Surg Oncol 22: S646\u2013S654.","DOI":"10.1245\/s10434-015-4862-z"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/65\/3\/65_EJ17-0276\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T16:06:45Z","timestamp":1570637205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/65\/3\/65_EJ17-0276\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej17-0276","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}